Madhya Pradesh Online Journal

Biosurgery Market Expected to Witness Massive Growth with a Tremendous CAGR of 9.23%, asserts DelveInsight

 Breaking News
  • No posts were found

Biosurgery Market Expected to Witness Massive Growth with a Tremendous CAGR of 9.23%, asserts DelveInsight

November 16
19:57 2022
Biosurgery Market Expected to Witness Massive Growth with a Tremendous CAGR of 9.23%, asserts DelveInsight
Biosurgery Market
The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2022-2027.

The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2022-2027. 

The biosurgery market is witnessing a positive growth owing to various factors such as the increasing incidence of cardiovascular diseases, increasing demand of plastic surgery, the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market. Therefore, the market for biosurgery is estimated to grow during the forecast period from 2022 to 2027.

Some of the key market players operating in the Biosurgery market include BD (NYSE: BDX), Baxter (NYSE: BAX), SAMYANG HOLDING CORPORATION, B. Braun Melsungen AG, Stryker (NYSE: SYK), Integra LifeSciences (NASDAQ: IART), Hemostasis LLC, Biom’Up, Pfizer Inc (NYSE: PFE), Ethicon US LLC (Johnson & Johnson Services Inc) (NYSE: JNJ), CryoLife Inc, Zimmer Biomet (NYSE: ZBH), Kuros Biosciences (SWX: KURN), Orthofix US LLC, Tissue Regenix (Tissue Regenix), Betatech Medical, Meril Life Sciences Pvt. Ltd, RTI Surgical (NASDAQ: SRGA), AROA BIOSURGERY LIMITED (ASX: ARX), BioCer Entwicklungs-GmbH, among others

DelveInsight’s “Biosurgery Market Insight & Forecast” report will offer an in-depth understanding of the Biosurgery market, further benefiting the competitors or stakeholders operating in the Biosurgery arena.

Biosurgery Overview

Biosurgery products are designed to reduce bleeding during various operations and to speed wound and surgical site healing. Due to their many benefits, including their efficacy, usability, and safety in various circumstances, these items are chosen in addition to conventional procedures (such as staples and sutures) for wound closure.

Interested to know more about the functioning of Biosurgery- Visit @ Biosurgery Operations & Working.

Biosurgery Market Insights

Among all the regions, North America is expected to dominate the global biosurgery market in the year 2021 and is expected to do the same during the forecast period from 2022 to 2027. Factors such as the increasing incidence of cancers such as prostate cancer and surge in the biosurgery products launch in the market are expected to increase the demand for biosurgery in the North America market.

According to the latest data published by American Cancer Society, Inc. in the year 2022, it is estimated that in the year 2022, in United States, there will be 268,490 new cases of prostate cancer. Moreover, biosurgery products could be used to remove the prostate gland, as they are safe, effective, prevent bleeding and initiate wound healing after the surgery. Therefore, the increasing incidence of cancers such as prostate cancer, can boost the demand of biosurgery, which could drive the overall biosurgery market forward over the forecast period (2022-2027). 

Furthermore, another factor that is responsible for the growth of biosurgery market is the surge in the biosurgery products launch in the market. For instance, in April 2021, Aroa Biosurgery, a soft tissue regeneration company, launched a new product named Myriad Morcells™, a morcellized (powder) format of Myriad Matrix™ which easily conforms to maximise interaction with uneven wound beds. Myriad Matrix™ is used during the surgical treatment of hidradenitis suppurativa, complex wounds and exposed vital structures.

In February 2020, Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, launched a large format version of its Endoform® Natural product in United States and Canadian markets, following its recent approval for reimbursement within the U.S. healthcare system. It is used to treat large surgical wounds with a single sheet of their extracellular matrix-based product.

Therefore, due to interplay of the factors mentioned above, there will be a higher demand for biosurgery, which would provide a conducive growth environment for the North American region in the biosurgery market.

To read more about why North America is leading the market growth in the Biosurgery market, get a snapshot of the Biosurgery market report.

Biosurgery Market Dynamics

As with the increasing incidence of cardiovascular diseases, the demand for biosurgery also increases. For instance, according to the latest data published by the British Heart Foundation in the year 2021, in 2019, in Asia, 32,376,834 people were affected with cardiovascular diseases, 12,543,833 individuals were diagnosed with coronary artery disease, and 8,111,044 population was detected with stroke. Thus, biosurgery products are used during the cardiovascular surgery, as they are safe, effective, prevent bleeding and initiate wound healing after the surgery. Therefore, the increasing incidence of cardiovascular diseases, can boost the demand of biosurgery, which could drive the overall biosurgery market forward over the forecast period (2022-2027).

Moreover, another key factor which is responsible for the growth of biosurgery market is the increasing demand of plastic surgery. For instance, according to the latest plastic surgery statistics report published in the year 2020, in America, out of 15.6 million of cosmetic operations, 2.3 million were cosmetic surgical procedures whereas 13.2 million cosmetic were minimally-invasive procedures. According to the source mentioned above, in 2020, reconstructive procedures were 6.8 Million (3% increase from 2019). Thus, increasing demand of plastic surgery, could boost the demand for biosurgery which in turn can provide a conductive growth environment for the biosurgery overall market.

Therefore, due to the aforementioned factors, biosurgery demand increases, which will surge the growth of the overall biosurgery market during the forecast period from 2022 to 2027.  

However, rising cost of surgical procedures and complications related to surgical procedures such as infection, pain and others, this can hamper the global biosurgery market growth.

Recent Breakthroughs in Biosurgery Market:

  • In February 2022, Gunze Limited, announced that it has received medical device approval to manufacture and sell TENALEAF™, the first sheet-type absorbable adhesion barrier made in Japan. During open surgery and minimally invasive surgery, this device gives surgeons a new choice that can facilitate simple manipulation, provide a modest amount of adhesive strength for repositioning, and allow for conformable insertion.
  • In December 2021, BD, a global medical technology company, announced that it has acquired Tissuemed, Ltd., a privately held company which has headquarter in Leeds, England it is an industry leader in developing self-adhesive surgical sealant films. Tissuemed’s lead product, Tissuepatch™, is a proprietary sealant technology that bonds to tissue to help control internal bleeding or stop leakage from surgical wounds.
  • In February 2022, Baxter International Inc, a leading global medical products company, announced acquisition of Seprafilm Adhesion Barrier which is used as an adjunct to limit the incidence, extent & severity of adhesions in certain pelvic and abdominal surgeries.

Key Players Proactively Working In the Biosurgery Market

Some of the key market players operating in the Biosurgery market include BD, Baxter, SAMYANG HOLDING CORPORATION, B. Braun Melsungen AG, Stryker, Integra LifeSciences, Hemostasis LLC, Biom’Up, Pfizer Inc, Ethicon US LLC (Johnson & Johnson Services Inc), CryoLife Inc, Zimmer Biomet, Kuros Biosciences, Orthofix US LLC, Tissue Regenix, Betatech Medical, Meril Life Sciences Pvt. Ltd, RTI Surgical, AROA BIOSURGERY LIMITED, BioCer Entwicklungs-GmbH, among others

Scope of the Biosurgery Market Report:

  • Geography Covered: Global
  • Forecast Period: 2022-2027
  • Key Biosurgery Companies: BD, Baxter, SAMYANG HOLDING CORPORATION, B. Braun Melsungen AG, Stryker, Integra LifeSciences, Hemostasis LLC, Biom’Up, Pfizer Inc, Ethicon US LLC (Johnson & Johnson Services Inc), CryoLife Inc, Zimmer Biomet, Kuros Biosciences, Orthofix US LLC, Tissue Regenix, Betatech, and others.
  • Market Segmentation By Product Type: Sealant, Haemostat, Bone Graft Substitute, Adhesion Barriers, And Others
  • Market Segmentation by Application: Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, And Others
  • Market Segmentation by End-User: Hospitals And Ambulatory Surgical Centers
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Table of Contents 

1

Report Introduction

2

Executive Summary

3

Regulatory and Patent Analysis

4

Key Factors Analysis

5

Biosurgery Porter’s Five Forces Analysis

6

COVID-19 Impact Analysis on Biosurgery Market

7

Biosurgery Market Layout

8

Biosurgery Global Company Share Analysis – Key 3-5 Companies

9

Biosurgery Companies and Product Profiles

10

Project Approach

11

KOL Views

12

DelveInsight Capabilities

13

Disclaimer

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Categories